Financial update

Revenue is ahead of board expectations, as a result of the benefit of sterling weakness and stronger than budgeted sales of Drug-Eluting Beads.

The company generated a small positive cash flow in the quarter, closing with cash and cash equivalents of GBP33.9 million (December 31, 2008: GBP33.6 million). A payment by AstraZeneca was received, in accordance with the terms of the agreements announced on December 22, 2008.

The board has approved a dividend of five pence per share which will be paid on Friday May 22, 2009 to shareholders on the register at the close of business on Friday May 1, 2009.